» Articles » PMID: 20579878

Structure-activity Relationships and in Vivo Activity of (1H-pyrazol-4-yl)acetamide Antagonists of the P2X(7) Receptor

Abstract

Structure-activity relationships (SAR) of analogues of lead compound 1 were investigated and compound 16 was selected for further study in animal models of pain. Compound 16 was shown to be a potent antihyperalgesic agent in both the rat acute complete Freund's adjuvant (CFA) model of inflammatory pain [Iadarola, M. J.; Douglass, J.; Civelli, O.; Naranjo, J. R. rain Res.1988, 455, 205] and the knee joint model of chronic inflammatory pain [Wilson, A. W.; Medhurst, S. J.; Dixon, C. I.; Bontoft, N. C.; Winyard, L. A.; Brackenborough, K. T.; De Alba, J.; Clarke, C. J.; Gunthorpe, M. J.; Hicks, G. A.; Bountra, C.; McQueen, D. S.; Chessell, I. P. Eur. J. Pain2006, 10, 537].

Citing Articles

The P2X7 Receptor: Central Hub of Brain Diseases.

Andrejew R, Oliveira-Giacomelli A, Ribeiro D, Glaser T, Arnaud-Sampaio V, Lameu C Front Mol Neurosci. 2020; 13:124.

PMID: 32848594 PMC: 7413029. DOI: 10.3389/fnmol.2020.00124.


Crystal structure and Hirshfeld surface analysis of -{2-[()-(4-methyl-benzyl-idene)amino]-phen-yl}-2-(5-methyl-1--pyrazol-3-yl)acetamide hemihydrate.

Chkirate K, Kansiz S, Karrouchi K, Mague J, Dege N, Essassi E Acta Crystallogr E Crystallogr Commun. 2019; 75(Pt 2):154-158.

PMID: 30800442 PMC: 6362653. DOI: 10.1107/S2056989018017747.


Recent Advances in CNS P2X7 Physiology and Pharmacology: Focus on Neuropsychiatric Disorders.

Bhattacharya A Front Pharmacol. 2018; 9:30.

PMID: 29449810 PMC: 5799703. DOI: 10.3389/fphar.2018.00030.


The potential of P2X7 receptors as a therapeutic target, including inflammation and tumour progression.

Burnstock G, Knight G Purinergic Signal. 2017; 14(1):1-18.

PMID: 29164451 PMC: 5842154. DOI: 10.1007/s11302-017-9593-0.


Purinergic Signalling: Therapeutic Developments.

Burnstock G Front Pharmacol. 2017; 8:661.

PMID: 28993732 PMC: 5622197. DOI: 10.3389/fphar.2017.00661.